117 related articles for article (PubMed ID: 11319288)
1. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
Am J Clin Oncol; 2001 Apr; 24(2):143-7. PubMed ID: 11319288
[TBL] [Abstract][Full Text] [Related]
2. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Pinto C; Marino A; De Pangher Manzini V; Benedetti G; Galetta D; Mazzanti P; Del Conte G; dell'Amore D; Piana E; Giaquinta S; Lopez M; Martoni A
Lung Cancer; 2006 May; 52(2):199-206. PubMed ID: 16542747
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
4. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
[TBL] [Abstract][Full Text] [Related]
5. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Astoul P; Picat-Joossen D; Viallat JR; Boutin C
Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714
[TBL] [Abstract][Full Text] [Related]
7. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
9. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.
Knuuttila A; Ollikainen T; Halme M; Mali P; Kivisaari L; Linnainmaa K; Jekunen A; Mattson K
Anticancer Drugs; 2000 Apr; 11(4):257-61. PubMed ID: 10898540
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
[TBL] [Abstract][Full Text] [Related]
12. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Andreopoulou E; Ross PJ; O'Brien ME; Ford HE; Priest K; Eisen T; Norton A; Ashley S; Smith IE
Ann Oncol; 2004 Sep; 15(9):1406-12. PubMed ID: 15319247
[TBL] [Abstract][Full Text] [Related]
13. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
Hastürk S; Tastepe I; Unlü M; Cetin G; Baris YI
J Chemother; 1996 Apr; 8(2):159-64. PubMed ID: 8708749
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
15. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
Purohit A; Moreau L; Dietemann A; Seibert R; Pauli G; Wihlm JM; Quoix E
Lung Cancer; 1998 Nov; 22(2):119-25. PubMed ID: 10022219
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
18. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
Portalone L; Antilli A; Nunziati F; Crispino C; de Marinis F; Friggeri L; Lombardi A; Lorusso V; Pronzato P; Sambiasi D; Signora M;
Tumori; 2005; 91(1):15-8. PubMed ID: 15849999
[TBL] [Abstract][Full Text] [Related]
20. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
O'Brien ME; Watkins D; Ryan C; Priest K; Corbishley C; Norton A; Ashley S; Rowell N; Sayer R
Ann Oncol; 2006 Feb; 17(2):270-5. PubMed ID: 16317014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
